Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial.
Azita Hajhossein TalasazParham SadeghipourHooman BakhshandehBabak Sharif-KashaniFarid RashidiMohammad Taghi BeigmohammadiKeivan Gohari MoghadamSomayeh RezaianAli DabbaghSeyed Hashem SezavarMohsen FarrokhpourAtefeh AbediniRasoul AliannejadTaghi RiahiMahdi YadollahzadehSomayeh LookzadehParisa RezaeifarSamira MatinOoria TahamtanKeyhan MohammadiElnaz ZoghiHamid RahmaniSeyed Hossein HosseiniSeyed Masoud MousavianHoma AbriPardis SadeghipourElahe BaghizadehFarnaz RafieeSepehr JamalkhaniAhmad AminBahram MohebbiSeyed Ehsan ParhizgarMahshid SoleimanzadehMaryam AghakouchakzadehVahid EslamiPooya PayandemehrHossein KhaliliHamed TalakoobTaranom TojariShadi ShafaghiSanaz TabriziHessam KakavandAlireza KashefizadehAtabak NajafiDavid JiménezAakriti GuptaMahesh V MadhavanSanjum SethiSahil A ParikhManuel MonrealNaser HadavandAlireza HajighasemiKhalil AnsarinMajid MalekiSaeed SadeghianAlexandru GrigoreanBob SiegerinkErica SpatzGregory PiazzaAjay J KirtaneBenjamin W Van TassellGregory Yoke Hong LipFrederikus Albertus KlokSamuel Z GoldhaberGregg StoneHarlan KrumholzBehnood BikdeliPublished in: Thrombosis and haemostasis (2023)
Atorvastatin 20 mg compared with placebo did not significantly reduce the 90-day composite of death, treatment with ECMO, or venous/arterial thrombosis. However, the point estimates do not exclude a potential clinically meaningful treatment effect, especially among patients who presented within 7 days of symptom onset. (NCT04486508).